The competition to Remestemcel-L in COVID-19, page-97

Hey, all. when gauging whether US$75,000 is a reasonable fee for MSB's ARDS treatment, here are results from a recent published study on per day ICU costs (with and without ventilator assist) in the US. It's NOT cheap:

Mean intensive care unit cost and length of stay were 31,574 +/- 42,570 dollars and 14.4 days +/- 15.8 for patients requiring mechanical ventilation and 12,931 +/- 20,569 dollars and 8.5 days +/- 10.5 for those not requiring mechanical ventilation.

Daily costs were greatest on intensive care unit day 1 (mechanical ventilation, 10,794 dollars; no mechanical ventilation, 6,667 dollars), decreased on day 2 (mechanical ventilation:, 4,796 dollars; no mechanical ventilation, 3,496 dollars), and became stable after day 3 (mechanical ventilation, 3,968 dollars; no mechanical ventilation, 3,184 dollars).

Adjusting for patient and hospital characteristics, the mean incremental cost of mechanical ventilation in intensive care unit patients was 1,522 dollars per day (p < .001).

Here is a link to the article and its abstract: https://www.researchgate.net/publication/7800750_Daily_cost_of_an_intensive_care_unit_day_The_contribution_of_mechanical_ventilation

Of course, if Remestemcel-L proves effective in

• getting people off ventilators;
• keeping them off ventilators;
• getting them out of ICU and hospital more quickly;
• providing more guaranteed health outcomes (80% likely to live instead of lingering on a ventilator for 15 days and then having a 30% chance of expiring, regardless);
• preventing the costs of longer-term health issues due to ARDS-related deterioration;
• etc., etc., etc.,

that US$75,000 for MSB's product looks positively cheap.